德克斯拉松使得多克索鲁比诱导的心力衰竭在接受高累积剂量的肉瘤患者中是一种罕见的事件
相关实验视频
Updated: May 21, 2025
08:09
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
Published on: June 7, 2018
9.7K
Haoyi Zheng1, Huichun Zhan2,3
1The Heart Center, Saint Francis Hospital, 100 Port Washington Blvd, Roslyn, NY, 11576, USA. Haoyi.Zheng@chsli.org.
Cardio-oncology (London, England)
|March 20, 2025
概括
德克斯拉松有效地防止了多克索鲁比诱导的心脏毒性在肉瘤患者,允许更高,更安全的剂量. 它在试验和实践中的不足利用限制了多克索鲁比.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 多克索鲁比对于瘤治疗至关重要,但会导致剂量依赖性心脏毒性.
- 德克斯拉松是FDA批准的唯一一种针对多克索鲁比毒性的心脏保护剂.
- 德克斯拉松在临床和研究中未得到充分利用,尽管其有效性已被证明.
研究的目的:
- 审查最近对肉瘤患者的瘤学试验中德克斯拉佐素的作用.
- 评估德克斯拉佐素在高累积剂量下对多克索鲁比辛心脏毒性的影响.
- 倡导在临床实践中增加德克斯拉佐的使用.
主要方法:
- 对当代三期肉瘤试验的审查.
- 在使用德克斯拉松和不使用德克斯拉松的试验中分析心力衰竭发病率.
- 检查关于德克斯拉佐克桑安全性和有效性的元分析.
主要成果:
- 一项禁止使用德克斯拉佐的试验显示,在360-450 mg/m2的多克索鲁比辛剂量下,心力衰竭为5.4%.
- 使用德克斯拉松的试验报告了罕见的心力衰竭,即使超过600 mg/m2.
- 德克斯拉松使得安全的多克索鲁比辛剂量>1000毫克/平方米,而不会增加心脏毒性.
结论:
- 德克斯拉松减轻了多克索鲁比辛的心脏毒性,并允许剂量升级.
- 对二次恶性瘤或降低疗效的担忧是毫无根据的.
- 建议在高剂量多克索鲁比辛治疗方案和高危患者中进行常规的前期使用德克斯拉佐克桑.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
356
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
356
01:26Heart Failure Drugs: Inotropic Agents
479
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
479
01:22Heart Failure Drugs: Diuretics
312
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
312
01:20Exercise and Cardiovascular Response
683
Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
683
01:22Heart Failure Drugs: β-Blockers
299
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
299